Breast Cancer Research and Treatment **20**: 207, 1991.

Author index, Volume 20

Abolafio G 19
Adams JB 145
Anderson K S25
Antman K S25
Arboit L 19
Ariad S 11
Attewell R 93
Ayash L S25

Baldetorp B 93
Beattie CW 125
Bell J 3,117
Bevilacqua P 195
Bezwoda WR 11
Blackburn GL 73
Blamey RW 3,117
Body G 185
Boracchi P 195
Borg Å 93
Bougnoux P 185
Buck H 43
Buzzard IM 73

Cerrotta AM 19
Chajes V 185
Charreau EH 133
Chlebowski TR 73
Ciocca DR 33
Coradini D 19
Couet C 185

Daidone MG 19
Das Gupta TK 125
De Young NJ 53
Depisch D 63
Dittrich C 63
Dixon PD 53
Dosne Pasqualini C 133

Elashoff R 73
Elias AD S25
Ellis IO 3,117
Elston CW 3
Ewers S-B 93
Eynard M 177

Falette N 177
Frei E S25

Galante E 19
Galea M 3
Garin E 177
Gasparini G 195
Gill PG 53
Gillis S S3
Gisslinger H 63
Griffin J S25
Grosvenor M 73
Gullick WJ 3

Hacene K 185
Hahnel E 167
Hahnel R 167
Haider K 63
Harvey J 167
Henney J 205
Horsfall DJ 53
Hunt M S25

Insull W Jr 73

Joyce R 167

Killander D 93
Korn EL 155
Kornek G 63
Kvinnsland S 25

Lanari C 133
Långström E 93
Lanson M 185
Lea OA 25
Lefebvre M-F 177
LeFloch O 185
Lensink IL 53
Linkesch W 63
Lipsett JA 85
Luk KH 85
Luque EH 33

Manni A 43
Marubini E 195
Mazanet R S25
Meggouh F 177
Mehta RR 125
Meiss R 133
Meli S 195

Neidhart JA S15
Nicholson RI 117

Odom-Maryon T 85
Osborne CK S1,S11

Panizzoni GA 195
Pap S S25
Patterson MP 85
Pazos P 133
Pearson D 3
Pelaez J S25
Pezner RD 85
Poller DN 3
Pozza F 195

Robertson JFR 117
Robins A 117
Rose D 73
Rosen H 109

Saez S 177
Scheithauer W 63
Schnipper L S25
Schwartz G S25
Seymour L 11
Silvestrini R 19
Simon R 155
Søreide JA 25
Sterrett G 167
Stierer M 109

Tepler I S25
Tilley WD 53

Valentinis B 19
Visonà A 195
Vora NL 85

Weber R 109
Wheeler C S25
Wong JYC 85
Wright C 43
Wynder EL 73

Breast Cancer Research and Treatment **20**: 209-212, 1991.

Subject index, Volume 20

adjuvant therapy
  chemotherapy and weight gain 75-76
  dietary fat reduction, review 73-84
  tamoxifen effectiveness vs. tumor cytosol protein content 25-32
age
  and hormone changes during chemotherapy 125-132
amenorrhea
  ovarian function loss during chemotherapy 125-132
amonafide
  Phase II trial in advanced breast cancer 63-67
aneuploidy
  and c-erbB-2, no association 3-10
animal models
  dietary fat vs. breast cancer growth and metastases 76-77
antigens
  see tumor antigens
autologous bone marrow transplantation
  use of GM-CSF S25-S29
  vs. hematopoietic growth factors S11-S14

bone marrow
  see autologous bone marrow transplantation
book review
  Setting Priorities for Effectiveness Research 205
breast-conserving management
  quantitation of cosmetic outcome 85-92

c-erbB-2 oncogene
  and nuclear size, S-phase in DCIS and invasive breast cancer 3-10
carboplatin
  in dose-intense combinations 155-166
carcinoembryonic antigen (CEA)
  effect of tamoxifen therapy 117-123
carcinogenesis
  MPA and MNU synergism in mouse mammary gland 133-138
chemotherapy
  amonafide, Phase II trial in advanced breast cancer 63-67
  endocrine profile and loss of ovarian function 125-132
  GM-CSF in dose-intensive S1-S29
  mathematical model for dose-intense combinations 155-166
cisplatin
  in dose-intense combinations 155-166
colony-stimulating factors
  see hematopoietic growth factors
cosmetic assessment
  in breast-conserving surgery 85-92
cyclophosphamide
  in dose-intense combinations 155-166
cytokines
  in hematopoiesis S3-S9
cytosol protein content
  correlation with positive nodes, low ER 25-32

dietary fat
  intake, and breast cancer outcome 74-75
  reduction as adjuvant therapy, review 73-84
  reduction programs 78-80
DNA ploidy
  see ploidy
dose intensity
  as a therapeutic strategy S11-S29
  mathematical model for selecting combinations 155-166
doxorubicin
  in dose-intense combinations 155-166
ductal carcinoma in situ
  c-erbB-2 overexpression and high S-phase 3-10

effectiveness research
  setting priorities, book review 205
EGF
  interactions with insulin, E, Pg in T47D cells 53-62
EGF receptor
  frequency of masking by endogenous ligands 177-183
  measuring occupied vs. unoccupied sites 177-183
elderly patients
  TLI, steroid receptors, and ploidy 19-24
endocrine profile
  during CMF chemotherapy 125-132
enzymes
  controlling tumor metabolism of estrogens 145-154
epidemiology
  dietary fat vs. breast cancer outcome 74-75
epidermal growth factor
  see EGF
ER-D5 antibody
  target, ER-associated protein p29, identity with hsp27 33-42
estrogen receptor
  and cytosol protein content 25-32
  and TLI, PgR, ploidy in elderly patients 19-24
  and tumor pS2 mRNA levels 167-175
  effects of tamoxifen therapy on tumor content 117-123
  status, vs. occupancy of EGF receptor sites 177-183
estrogen receptor associated protein (p29)
  identity with heat shock protein hsp27 33-42
estrogens
  inducible pS2 in uninvolved breast tissue 167-175
  interactions with insulin, EGF, Pg in T47D cells 53-62
  metabolic controls on tumor concentration (review) 145-154

fat
  intake reduction as adjuvant therapy, review 73-84
fatty acids
  composition of tumor phosphatidylcholine and prognosis 185-194
feasibility trials
  dietary fat reduction regimens 78-80
flow cytometry
  debris correction for prognostic significance of S-phase 93-108
  ploidy and S-phase vs. c-erbB-2 overexpression 3-10
fluorouracil
  in dose-intense combinations 155-166

granulocyte-macrophage colony-stimulating factor
  see hematopoietic growth factors
growth factors, hematopoietic
  see hematopoietic growth factors

heat shock proteins
  hsp27 identity with ER-associated p29 33-42
hematopoietic growth factors
  in high-dose chemotherapy S11-S29
  in peripheral blood progenitor cell collection S25-S29
  preclinical studies S3-S9
  symposium S1-S29
HER-2/*neu*
  see c-erbB-2 oncogene
high-dose chemotherapy
  hematopoietic support S11-S29
histologic grading
  and nuclear pleomorphism in prognosis 109-116
hormone dependence
  MCF-7 cells in serum-free soft agar 43-52
hormone levels
  during chemotherapy 125-132

IGF-I
  in E and Pg stimulated growth of MCF-7 cells 43-52
insulin
  interactions with E, Pg, EGF in T47D cells 53-62
insulin-like growth factors
  see IGF-I

interleukin-3 (IL-3)
with GM-CSF in hematopoiesis S3-S9

leukopenia
effect of protection on choice of dose-intense drug combinations 155-166
ligand dissociation
assay of occupied vs. unoccupied EGF receptor 177-183
lipid composition
low stearic acid in membrane phosphatidylcholine and poor prognosis 185-194
lymphatic vessel invasion
vs. other prognostic factors 195-204

mast cell growth factor
in hematopoiesis S3-S9
mathematical models
for selecting dose-intense drug combinations 155-166
MCF-7 cells
hormone dependence in serum-free soft agar 43-52
medroxyprogesterone acetate (MPA)
potentiation of MNU mammary carcinogenesis in mice 133-138
membrane lipids
low stearic acid in phosphtidylcholine and poor prognosis 185-194
menopausal status
and pS2 mRNA in uninvolved breast tissue 167-175
metabolism
and control of tumor estrogen levels 145-154
monoclonal antibodies
ER-D5 (anti-p29) and C11 (anti-hsp27), common target 33-42
morphometry
nuclear size and c-erbB-2 overexpression 3-10
mouse mammary tumors
MPA and MNU synergism in carcinogenesis 133-138

N-methyl-N-nitrosourea (MNU)
MPA potentiation of carcinogenesis 133-138
nodal status
and peritumoral lymphatic vessel invasion 195-204
cytosol protein content and positive nodes 25-32
positive nodes vs. S-phase and ploidy in prognosis 93-108
nuclear pleomorphism
and prognosis in node-negative tumors 109-116
nuclear size
and c-erbB-2 overexpression 3-10

obesity
and hormone changes during chemotherapy 125-132
ovarian function
loss during chemotherapy, endocrine profile 125-132

PDGF
see platelet-derived growth factor
peripheral blood progenitor cells
in hematopoietic support for high-dose chemotherapy S25-S29
phosphatidylcholine
low stearic acid content and poor prognosis 185-194
PIXY321
IL-3/GM-CSF hybrid in hematopoiesis S3-S9
platelet-derived growth factor (PDGF)
in plasma, correlation with tumor burden 11-17
ploidy
and S-phase for prognosis 93-108
and TLI, steroid receptors in elderly patients 19-24
progesterone receptor
and TLI, ER, ploidy in elderly patients 19-24
and tumor pS2 mRNA levels 167-175
progestins
effects on metabolic controls of estrogen levels 145-154
MPA potentiates MNU mammary carcinogenesis in mice 133-138
T47D inhibition overcome by EGF 53-62

prognostic factors
cytosol protein content 25-32
dietary fat intake 75
elevated plasma PDGF 11-17
low stearic acid in phosphatidylcholine and poor outcome 185-194
mitotic index 185-194
nuclear pleomorphism in node-negative tumors 109-116
peritumoral lymphatic vessel invasion 195-204
prospective S-phase and ploidy 93-108
prolactin
independence of TGFα, IGF-I in stimulating MCF-7 cells 43-52
proliferative rate
and c-erbB-2 overexpression 3-10
vs. lymphatic vessel invasion in prognosis 195-204
see also thymidine labeling index, S-phase
protein content in cytosol
correlation with positive nodes, low ER 25-32
pS2
mRNA in uninvolved breast tissue as well as tumor 167-175

R5020
antiproliferative effects in T47D cells 53-62

S-phase
and c-erbB-2 overexpression 3-10
and ploidy for prognosis 93-108
stearic acid
low levels in tumor phosphatidylcholine and poor prognosis 185-194
stem cells
peripheral blood progenitor cells in high-dose chemotherapy S25-S29
surgery
breast conservation, cosmetic assessment 85-92

T47D cells
interactions of EGF, insulin, estrogen, and progestins 53-62
tamoxifen
effectiveness in protein-rich tumors 25-32
therapy effects on ER and tumor antigens 117-123
TGFα
in estradiol-stimulated growth of MCF-7 cells 43-52
TGFβ
and growth inhibition by 4-hydroxy tamoxifen 43-52
thiotepa
in dose-intense combinations 155-166
thrombocytopenia
effect of protection on choice of dose-intense drug combinations 155-166
thymidine labeling index (TLI)
and steroid receptors, ploidy, in elderly patients 19-24
TLI
see thymidine labeling index
toxicities
model predictions for drug combinations 155-166
transforming growth factors
see TGFα, TGFβ
tumor antigens
effects of tamoxifen therapy 117-123
tumor size
and cytosol protein content 25-32
and peritumoral lymphatic vessel invasion 195-204

weight gain
and adjuvant chemotherapy 75-76